113
Participants
Start Date
June 8, 2020
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Liposomal Bupivacaine
Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity
Quadratus Lumborum Block
"Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients receive a second liposomal bupivacaine injection (RESQU block) on day 4 after surgery"
Questionnaire Administration
Ancillary studies
M D Anderson Cancer Center, Houston
National Cancer Institute (NCI)
NIH
M.D. Anderson Cancer Center
OTHER